

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Evaluation of leukocyte counts and neutrophil-to-lymphocyte ratio as predictors of local recurrence of feline injection site sarcoma after curative intent surgery**

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1722744> since 2020-01-13T14:02:41Z

*Published version:*

DOI:10.1111/vco.12534

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1       **EVALUATION OF LEUKOCYTE COUNTS AND NEUTROPHIL-TO-LYMPHOCYTE**  
2       **RATIO AS PREDICTORS OF LOCAL RECURRENCE OF FELINE INJECTION SITE**  
3       **SARCOMA AFTER CURATIVE INTENT SURGERY**

6       **Abstract**

7       Local recurrence (LR) is the major concern in the treatment of feline injection-site sarcoma (FISS).  
8       Pretreatment leukocyte counts and ratios have been reported as diagnostic and/or prognostic  
9       markers in human and canine oncology. The aim of this retrospective study was to explore the  
10       prognostic impact on LR and overall survival time (OST) of pretreatment neutrophil-to-lymphocyte  
11       ratio (NLR), white blood cell count (WBCC), neutrophil count (NC) and lymphocyte count (LC) in  
12       cats with surgically excised FISS.

13       Eighty-two cats with histologically confirmed FISS at first presentation, without distant metastases,  
14       and with available pretreatment hematological analyses were retrospectively enrolled. The  
15       correlation of NLR, WBCC, NC, LC with tumor variables and patient variables was explored. NLR  
16       was correlated with tumor size ( $P$  0.004), histological pattern of tumor growth ( $P$  0.024) and  
17       histotype ( $P$  0.029), while WBCC and NC were associated with ulceration ( $P$  0.007,  $P$  0.011) and  
18       pattern of growth ( $P$  0.028,  $P$  0.004). No significant relationships emerged between LC and any of  
19       the considered variables. The impact of NLR, WBCC, NC, LC on LR and OST was then estimated  
20       in univariate and multivariate analysis. In univariate analysis, NLR, WBCC, NC were significant  
21       prognostic factors for both LR and OST. NLR, WBCC, NC remained prognostic in multivariate  
22       analysis for LR but not for OST. When NLR, WBCC and NC were jointly analyzed, WBCC was  
23       the marker with the greater impact on LR. Preoperative NLR, WBCC, and NC may aid in  
24       identifying cats at higher risk of LR.

35

36

## 37 **Introduction**

38 Feline injection-site sarcoma (FISS) is among the four most common feline skin cancers.<sup>1</sup> Although  
39 it was initially hypothesized that the etiology of FISS is strictly related to vaccination<sup>2</sup>, it is  
40 nowadays widely accepted that this tumor can develop following any stimulus that causes chronic  
41 local inflammation of the subcutis or muscles.<sup>3-7</sup> Despite the relatively low incidence of distant  
42 metastasis (0–28%)<sup>8-11</sup>, FISS tends to be locally aggressive and local recurrence (LR) represents the  
43 major concern, with reported rates as high as 14%–42%,<sup>8,12-15</sup> therefore, achieving adequate control  
44 of local disease through wide-margin/radical surgical excision is the cornerstone in oncological  
45 management of the tumor<sup>14,16</sup>.

46 The prognostic impact of different variables on LR and overall survival time (OST) after wide-  
47 margin/radical excision has been widely explored in the last two decades. Histological grading is  
48 considered one of the most important prognostic factors for canine soft tissue sarcomas<sup>17</sup> (STS);  
49 nonetheless, the traditional three-tier grading system has shown limited value in predicting LR and  
50 outcome for FISS.<sup>11,13,17-18</sup>

51 Completeness of excision is indeed crucial in obtaining long-term control of the local disease;  
52 however, LR has been reported even in the presence of histologically non-infiltrated margins,  
53 suggesting that factors other than completeness of excision may be implicated in tumor  
54 relapse.<sup>11,13,19</sup>

55 Although other variables, such as size and location of the tumor, expertise of the surgeon, recurrent  
56 tumors, p53 expression, mitotic count, and differentiation, have been proposed as predictors of LR,  
57 there is still no consensus on which factors other than completeness of excision should be taken into  
58 account to predict prognosis.<sup>8,13,15,20,21</sup> Hence, readily available and accurate variables that can aid  
59 in identifying cats at higher risk of LR are desirable to improve oncological management of these  
60 patients.

61 Pretreatment neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammatory response  
62 that has been reported to be a useful prognostic tool for several solid tumors in human medicine,  
63 including STS.<sup>22</sup> Recently, the veterinary literature has reflected growing interest in peripheral  
64 blood cell abnormalities as diagnostic and prognostic markers for both neoplastic and inflammatory  
65 conditions. A few papers have explored the prevalence of different leukocyte populations and T-  
66 lymphocyte subsets in tumor-bearing versus healthy dogs.<sup>23-26</sup> Furthermore, leukocyte counts and  
67 ratios have been proposed as diagnostic and prognostic tools for dogs with lymphoma,  
68 osteosarcoma, mast cell tumors, and STS.<sup>27-31</sup> Yet, the prognostic impact of peripheral leukocyte

69 counts and ratios, including NLR, has not been assessed in feline medicine. Given the promising  
70 results described in canine oncology, this retrospective study aimed to explore the prognostic  
71 impact on LR of pretreatment white blood cell count (WBCC), neutrophil count (NC), lymphocyte  
72 count (LC), and NLR in cats with newly diagnosed, surgically excised FISS. As a secondary aim,  
73 the impact of leukocyte counts and NLR on OST was assessed.

#### 74 **Materials and Methods**

75 Records (January 2002 to December 2017) from the XX and YY were searched for client-owned  
76 cats with histologically confirmed FISS. The main inclusion criteria were: FISS at first presentation,  
77 absence of distant metastasis (assessed by total body contrast-enhanced CT or thoracic radiography  
78 and abdominal ultrasound), and treatment by wide-margin/radical surgical excision with three to  
79 five cm lateral margins and two deep fascial planes or limb or tail amputation. To be eligible for  
80 inclusion, presurgical complete hematological data with leukocyte differential (within 45 days  
81 before surgery) had to be available. Exclusion criteria were: (1) neoadjuvant chemotherapy and/or  
82 radiotherapy, (2) adjuvant radiotherapy, (3) FIV and/or FeLV positivity, (4) administration of  
83 antibiotics and/or corticosteroids within two months before surgery, and (5) lack of availability of  
84 postoperative follow-up information.

85 Data retrieved from the medical records of included cats were: signalment (breed, sex, age, weight),  
86 characteristics of the primary tumor (location, size at clinical examination, ulceration), presurgical  
87 laboratory data (leukocyte counts, hyperglycemia as indicator of stress), concomitant diseases if  
88 present, histological findings (histotype, necrosis, grading, pattern of growth, margin status), and  
89 outcome (time to LR, time to metastases, cause of death, OST).

90 For pretreatment hematological analysis, blood was collected in EDTA, and CBC parameters,  
91 including leukocyte differential, were measured with the same laser-based analyzer at the laboratory  
92 of one of the two institutions (ADVIA®120 Hematology System, Siemens Diagnostics).  
93 Instrumental differential was also checked microscopically on May-Grunwal-Giemsa stained  
94 smears. NLR was calculated as the ratio of the absolute count of neutrophils to lymphocytes. When  
95 the biochemistry profile was available, hyperglycemia was retrieved and considered as a possible  
96 marker of stress that could have altered the absolute values of both neutrophils and lymphocytes  
97 and, as a consequence, the NLR. Variations from normal values of WBCC, NC, and LC were  
98 defined based on the reference intervals reported in Table 1.

99 Histopathological specimens were processed and examined by the same pathologist at each  
100 institution (XX, XY). Variables retrieved from the histological reports were: histotype, pattern of  
101 growth<sup>32</sup>, necrosis (semiquantitatively scored as 0 when absent, 1 when <25%, 2 when 25%-50%,  
102 and 3 when >50%), histological grading<sup>17</sup> if available, and status of surgical margins<sup>13</sup> (infiltrated

103 or non-infiltrated). Surgical margins were evaluated combining, at trimming, two techniques: radial  
104 sectioning along the longest axis of the sample (perpendicular margins)<sup>33</sup>, and tangential (*en face*)  
105 sectioning/3D technique<sup>13,33</sup>.

106 Follow-up information was obtained from the clinical records or by telephone conversations with  
107 cat owners or referring veterinarians. Time to LR and OST were the primary and secondary  
108 endpoints, respectively. Time to LR was calculated from the date of surgery to the date of LR,  
109 defined as a cytologically or histologically confirmed FISS growing within two cm from the scar of  
110 previous excision. OST was calculated from the date of surgery to the date of death or euthanasia;  
111 cause of death was classified as either tumor related or tumor unrelated.

112

### 113 *Statistical analysis*

114 Statistical analysis evaluated the relationship between NLR, WBCC, NC, and LC and the following  
115 variables: age, glycemia, tumor size, ulceration, concomitant diseases, tumor necrosis, tumor  
116 histotype, and histological pattern of growth. The impact of NLR, WBCC, NC, and LC on LR and  
117 OST was then assessed.

118 Pearson coefficient ( $r$ ) was used to assess the linear correlation between NLR, WBCC, NC, and LC  
119 and continuous variables (tumor size, glycemia, age). Results were reported as estimated correlation  
120 coefficient and 95% confidence intervals (CI). The strength of the correlation was interpreted  
121 following the rule of thumb.<sup>34</sup> The null hypothesis of the absence of correlation between two  
122 variables was tested by  $t$  statistics.

123 For categorical variables (ulceration, concomitant diseases, necrosis, histotype, pattern of growth),  
124 the distributions of NLR, WBCC, NC, and LC for each modality were reported as: minimum, Q1  
125 (25%), mean, median, Q3 (75%), and maximum. As NLR, WBCC, NC, and LC were non-normally  
126 distributed, non-parametric tests were used to compare the distributions of the above-mentioned  
127 variables in the classes of categorical variables. Wilcoxon rank sum test with continuity correction  
128 was used for the variables with two modalities and Kruskal-Wallis test for the variables with three  
129 modalities.

130 The probability of being free of LR during follow-up was estimated by the Kaplan-Meier method.  
131 For cats that died without developing LR, times to death were censored to the death date, assuming  
132 independence between time to LR and time to death without LR. Patients lost to follow-up were  
133 censored at the time of the last contact. However, since the above cited independence assumption  
134 could not be determined on the basis of the available follow-up data, we also reported the bounds in  
135 which the correct estimates of LR free survival it is expected to lie, avoiding the assumption of  
136 independence.<sup>35</sup>

137 The probability of surviving during follow-up was estimated by the Kaplan-Meier method. Cox  
138 regression model was used to explore the prognostic impact of NLR, WBC, NC, LC and all other  
139 examined clinical and pathological variables on LR and OST. Firstly, univariate analysis was  
140 performed; then, a multivariate model was used to evaluate the prognostic role of each  
141 hematological value, adjusted for the clinical and pathological variables which resulted statistically  
142 significant in univariate analysis. For OST analysis, the maximum number of variables that could  
143 be included in the model was determined following the EPV rule.<sup>36</sup> For LR analysis, a less  
144 conservative rule<sup>37</sup> was applied, thus results of this analysis should be considered preliminary. A  
145 backward selection procedure was used to obtain a final model that included only statistically  
146 significant variables. To assess the robustness of multivariate analysis, bivariate models were also  
147 performed adjusting NLR, WBCC, NC for each one of the clinical and pathological variables.  
148 Categorical variables were included into the model as dummy variables, while continuous variables  
149 were included in their original measurement scale. For these latter, the possible non-linear  
150 relationship, was evaluated by regression cubic splines and the contribution of non-linear terms was  
151 tested by the likelihood ratio test. Results were reported as cause-specific hazard ratios for LR and  
152 hazard ratios for OST, and 95% CI. The Wald test was used to assess the significance of the  
153 regression coefficients of the model. No competing risks were considered for LR, as this event was  
154 recorded regardless of the occurrence of distant metastases. Predictive accuracy of the survival  
155 model was determined by calculating the area under the curve (AUC) extended for survival analysis  
156 (Harrell C statistic). Time-dependent ROC curves were used to find the best cut-off values for NLR,  
157 WBCC, and NC on the basis of the Youden Index (i.e. sensitivity + specificity).<sup>38</sup>  
158 Median follow-up time was estimated with the reverse Kaplan-Meier method.<sup>39</sup>  
159 All statistical analyses were performed with a software package (R-Software; [www.r-project.org](http://www.r-project.org))  
160 and a *P* value  $\leq 0.05$  was considered significant.

161

162

## 163 **Results**

164 Eighty-two cats fulfilled the inclusion criteria of the study, including 41 neutered females, 38  
165 castrated males, two intact females, and one intact male. Cat breeds included 71 domestic  
166 shorthairs, three Persians, three Carthusians, two Siamese, two Norwegians, and one Maine Coon.  
167 Median age at presentation was 11 years (range 6–18 years), and median weight was 4.5 kg (range  
168 2.5–8.5 kg).

169 Tumor size at the longest diameter was available in 81 cats, and median tumor diameter was four  
170 cm (range 0.7–15 cm). Tumor location was interscapular in 53 (64%), thoracic wall in 17 (21%),

171 abdominal wall in 8 (10%), and tail and limbs in 4 (5%). In 8 cats (10%) the tumor was ulcerated at  
172 presentation.

173 Pretreatment hematology analyses were performed a median of 16.5 days before surgery (range 1 –  
174 45 days) and revealed leukocytosis in 6 (7%) cats, leukopenia in 22 (27%), neutrophilia in 6 (7%),  
175 neutropenia in 12 (15%), and lymphopenia in 48 (59%); 29 patients (35%) had leukocyte values  
176 within the normal ranges. Glycemia was available for 78 patients (95%), of which 23 (30%) were  
177 hyperglycemic and 46 (59%) normoglycemic.

178 Concomitant diseases were recorded in 25 cats (30%) at the time of surgical consultation and  
179 included: chronic kidney disease (n=9), hyperthyroidism (n=4), chronic rhinitis (n=2), urinary tract  
180 infection (n=2), cardiac hypertrophy (n=2), benign keratin cyst (n=1), gastroenteropathy (n=2),  
181 diabetes (n=1), and allergic dermatitis (n=2).

182 Total body contrast-enhanced CT was performed in all but three patients that had thoracic  
183 radiographs and abdominal ultrasound. Seventy cats (85%) were treated with surgery alone, and 12  
184 (15%) received adjuvant chemotherapy (Doxorubicin 1 mg/kg IV every 3 weeks for 4 cycles in 6  
185 cats; Carboplatin 200 mg/m<sup>2</sup> IV every 3 weeks for 4 cycles in 6 cats).

186 Histopathological report described 52 fibrosarcomas (64%), 11 pleomorphic sarcomas (13%), and  
187 19 malignant fibrous histiocytomas (23%). Pattern of growth was available in 79 cases and was  
188 considered expansile in 36 tumors (46%) and infiltrative in 43 (54%). Necrosis was scored 0 in 15  
189 tumors (18%), 1 in 8 (10%), 2 in 29 (35%), and 3 in 28 (34%); in 2 cases the percentage of necrosis  
190 was not reported. Histological grading was available in 62 reports: 9 tumors were classified as  
191 grade I (15%), 26 as grade II (42%), and 27 as grade III (43%). Surgical margins were non-  
192 infiltrated in 65 specimens (79%) and infiltrated in 17 (21%).

193 At the end of the study, ten cats were alive without signs of local and/or distant relapse, 14 were lost  
194 to follow-up, and 58 were dead, including 24 that died of tumor-related causes and 34 that died of  
195 causes other than FISS, including chronic kidney disease (n=16), hypertrophic cardiomyopathy  
196 (n=3), intestinal lymphoma (n=4), car accident (n=3), acute pancreatitis (n=2), oral squamous cell  
197 carcinoma (n=2), recurrent urethral obstruction (n=2), meningioma (n=1), transitional cell  
198 carcinoma of the urinary bladder (n=1). Of the 24 cats that died because of FISS, 17 had a LR, three  
199 had LR and pulmonary metastasis, and the remaining four cats had pulmonary metastasis alone.  
200 Median time to LR was not reached (Figure 1). The estimates reported in Figure 1 are based on the  
201 assumption of independence between time to relapse and time to death, which could not be  
202 evaluated. However, it is possible to obtain intervals (bounding) into which the estimates are  
203 expected to lie if the assumption were not tenable. For example, at 550 and 1100 days the Kaplan-

204 Maier estimated probability of being free from LR is 78% and 70% respectively, with a  
205 corresponding bounding of 57-81% and 43-78%.

206 Median OST was 975 days (Figure 2). Median follow-up time was 1790 days.

207

208 *White blood cell count, neutrophil count, lymphocyte count and neutrophil-to-lymphocyte ratio*

209 WBCC and NC were significantly higher in ulcerated tumors ( $P$  0.007;  $P$  0.011). WBCC, NC and  
210 NLR were significantly higher in histologically infiltrative FISS ( $P$  0.028;  $P$  0.004;  $P$  0.024).  
211 (Tables 2 and 3). NLR was also significantly higher in fibrosarcomas ( $P$  0.029) and was correlated  
212 with tumor size ( $r$  0.3215;  $P$  0.004). None of the tested variables showed a relationship with LC  
213 (Tables 2 and 3).

214 In univariate analysis, a statistically significant prognostic impact on LR was found for WBCC ( $P$   
215 0.003), NC ( $P$  0.003), NLR ( $P$  0.015) but not for LC. The hazard of LR increased with increasing  
216 values of WBCC, NC and NLR (Table 4). With regards to diagnostic accuracy, for WBCC AUC  
217 was 0.695 at one year, 0.614 at two years and 0.599 at three years, with best estimated cut-off of  
218  $10.270 (\times 10^3/\mu\text{L})$  at one year (sensitivity=0.543; specificity=0.777),  $11.240 (\times 10^3/\mu\text{L})$  at two years  
219 (sensitivity=0.380; specificity=0.827), and  $11.460 (\times 10^3/\mu\text{L})$  at three years (sensitivity=0.287;  
220 specificity=0.840). For NC, AUC was 0.731 at one year, 0.653 at two years and 0.664 at three  
221 years, with best estimated cut-off of  $4.960 (\times 10^3/\mu\text{L})$  at one year (sensitivity=0.831;  
222 specificity=0.542) and two years (sensitivity=0.695; specificity=0.523), and  $6.940 (\times 10^3/\mu\text{L})$  at  
223 three years (sensitivity=0.482; specificity=0.791). For NLR, AUC was 0.630 at one year, 0.568 at  
224 two years, and 0.585 at three years. The optimal cut-off value for NC to predict LR at one year was  
225 1.823, which yielded a sensitivity of 0.947 and a specificity of 0.296; the optimal estimated cut-off  
226 at two and three years was 3.654 (sensitivity=0.525; specificity=0.660) and 3.654  
227 (sensitivity=0.523; specificity=0.669).

228 WBCC ( $P$  0.011), NC ( $P$  0.014) and NLR ( $P$  0.028) were prognostic for OST as well, with  
229 increasing hazard of death for increasing values of WBCC, NC and NLR (Table 4). LC was not  
230 prognostic for OST.

231 Of the examined clinical and pathological variables, concomitant diseases, ulceration, histological  
232 pattern of growth and margins status were prognostic in univariate analysis for LR, while age,  
233 ulceration, tumor size, and margins status were prognostic for OST (Tab 4).

234 In multivariate analysis, WBCC ( $P$  0.003), NC ( $P$  0.004) and NLR ( $P$  0.016) remained  
235 independently prognostic for LR (Table 5). However, when WBCC, NC and NLR were considered  
236 together in Cox regression model, only WBCC remained prognostic for LR ( $P$  0.012). Concomitant  
237 diseases, ulceration, and margin status remained prognostic as well, while pattern of growth



238 (expansile VS infiltrative) was removed from the model by backward selection procedure because it  
239 was no longer statistically significant (Table 5). Bivariate models confirmed the results of the  
240 multivariate analysis.

241 For OST, none of the clinical/pathological variables that were significant in univariate analysis  
242 (age, ulceration, tumor size and margins) was removed from the multivariate model by the  
243 backward procedure. WBCC, NC and NLR were not confirmed to be prognostic for OST in the  
244 multivariate model. Age, ulceration, margins and tumor size remained prognostic (Table 6).

245

246

247

## 248 **Discussion**

249 In the study population, pretreatment NLR, WBCC, and NC had a prognostic impact in univariate  
250 analysis on both LR and OST in cats with FISS at first presentation that underwent curative-intent  
251 surgery. LC, conversely, was not useful in predicting LR or OST. However, NLR, WBCC and NC  
252 were not confirmed to be prognostic for OST in the multivariate model, considering other clinical-  
253 pathological variables.

254 Surprisingly, when WBCC, NC, NLR were considered together in the Cox regression model, only  
255 WBCC remained prognostic for LR, while NLR and NC lost their significance. This finding is in  
256 contrast with previous reports in human and canine oncology.<sup>22,27,31</sup> Indeed, NLR and other  
257 leukocyte ratios reportedly have higher prognostic impact than leukocyte counts due to their greater  
258 stability and lower susceptibility to fluctuations of single cell populations caused by  
259 pathophysiological changes.<sup>27,31</sup> Since NLR takes into account both the impact of variations of NC  
260 and LC, the fact that NLR was inferior in predicting LR may be due to the lack of significance of  
261 LC; inclusion of this variable in the ratio may have reduced the prognostic significance of NLR.  
262 The fact that, despite having a higher proportion of lymphopenic rather than neutrophilic cats in the  
263 study population, LC was not correlated with LR nor OST, further corroborates this consideration.  
264 Similarly, as neutrophils constitute the majority of WBC in cats, the higher impact of WBCC  
265 compared with NLR may simply reflect the higher contribution of NC to this value. A recent paper  
266 evaluated NC and morphology in 517 cats with various diseases and reported a higher mortality for  
267 neutrophilic patients.<sup>40</sup> Although it is difficult to extrapolate whether oncological cats were included  
268 in the study, this finding corroborates the role of neutrophilic immune response in the feline  
269 species.<sup>40</sup> Nonetheless, in light of these considerations, it is surprising that NC lost its significance  
270 as well; however, this result should be considered cautiously, and further studies on a wider sample  
271 size are warranted to confirm the superiority of WBCC in predicting LR in FISS.

272 Among the examined tumor variables, pattern of tumor growth was the only one that showed a  
273 significant correlation with all the hematological variables in univariate analysis; indeed, patients  
274 with infiltrative tumors tended to have higher values of pretreatment WBCC, NC, and NLR. This  
275 result may suggest a relationship between pattern of tumor growth and the clinical behavior of  
276 FISS, with invasive tumors showing a more aggressive behavior that triggers an immune response  
277 with higher values of WBCC, NC, and NLR. Although histological pattern of growth has not been  
278 previously studied in FISS, this finding is consistent with a previous report on canine STS, where  
279 histologically invasive variants were associated with higher recurrence rates.<sup>32</sup> However, this  
280 consideration should be considered with caution, as in multivariate analysis tumor pattern of growth  
281 was not prognostic for LR, and the prognostic impact of this variables should be further  
282 investigated in future studies.

283 While NLR did not show any correlation with tumor ulceration, both NC and WBCC were  
284 associated with such variable. It might be argued that the better predictive accuracy of the leukocyte  
285 count is due to its correlation with tumor ulceration, which is a well-known prognostic factor for  
286 other solid tumors<sup>41</sup>; however, even though in our study ulceration was prognostic for both LC and  
287 OST, its significance in FISS should be confirmed in further studies in order to accept or refuse this  
288 hypothesis.

289 Other histological and clinical tumor variables were inconsistently correlated with the above-  
290 mentioned parameters, with presence of ulceration influencing WBCC and NC but not NLR, and  
291 tumor histotype and size influencing NLR. Tumor necrosis was not correlated with any of the  
292 above-mentioned hematological parameters, perhaps because necrosis remains circumscribed  
293 within the tumor pseudo capsule, that may hide it to the immunity system, thus precluding an  
294 immune response against it.

295 In the present study, we proposed different cut-offs for NLR, WBCC, and NC for prediction of LR  
296 at one, two, and three years, as the different follow-up times of the included patients precluded the  
297 determination of a single cut-off value. However, since the majority of events happened during the  
298 first year of follow-up, the cut-off at one year should be considered the most reliable, as suggested  
299 by the higher sensitivity and specificity of this value compared with the cut-offs at two and three  
300 years. These values should be considered barely preliminary, and more reliable cut-offs need to be  
301 determined in prospective studies on a larger population in order to allow validation on an  
302 independent sample.

303 The estimated cut-offs for leukocyte counts in our study population fall in their physiological  
304 ranges. However, it should be noticed that in the study design it was decided to consider leukocyte  
305 counts as continuous rather than categorical variables, and this decision was mainly due to the

306 explorative nature of the study. In fact, since to the authors' knowledge no previous papers have  
307 examined the significance of leukocyte fluctuations in feline oncology, it would have been  
308 misleading to establish empiric cut-offs. As a consequence, our results and the estimated cut-offs on  
309 the present study population suggest that for each increase in the WBCC and NC determines an  
310 increase in the hazard of LR, regardless of absolute alterations in the physiological ranges of  
311 leukocyte counts.

312 Cut-off values for NLR, WBCC, and NC were estimated for the prediction of LR but not OST. LR  
313 was a measurable outcome, even in the retrospective setting of this report, as cytological or  
314 histological biopsies were always performed to confirm it; on the other hand, OST may have been  
315 influenced by the decision of the owners to euthanize their cat and was thus considered a less  
316 reliable endpoint.

317 Which variables should be considered when planning treatment and predicting prognosis in FISS is  
318 an open debate; however, several papers have shown that the recurrence rate is significantly lower  
319 for cats with histologically non-infiltrated margins versus infiltrated margins, and completeness of  
320 excision has been reported to be a prognostic factor for survival.<sup>11,13,15</sup> Consistently with previous  
321 studies, margin status resulted prognostic for both LR and OST in our report. In the bivariate model  
322 that was performed as a more robust analysis to confirm the results of the multivariate model, the  
323 prognostic impact of margin status on both LR and OST was confirmed. Furthermore, even though  
324 our primary aim was to evaluate the prognostic impact of leukocyte counts and NLR on LR and  
325 OST, other potentially prognostic clinical and pathological variables were included in the survival  
326 analysis. Ulceration resulted significantly prognostic for both LR and OST. Although ulceration has  
327 not been previously reported to be prognostic for other canine or feline soft tissue sarcomas, it is  
328 considered as negative prognostic factor for other solid tumors, such as canine mast cell tumors<sup>41</sup>. It  
329 may thus be hypothesized that this characteristic is correlated with a more aggressive clinical  
330 behavior that causes a rapid tumor growth and subsequent disruption of the cutis.

331 Other clinical-pathological variables that had a prognostic impact were concomitant diseases for  
332 LR, and age and tumor size for OST; however, given the low numerosity of events in this study  
333 population, it would be speculative to draw conclusions from these results, especially considering  
334 that such variables resulted prognostic for only one of the considered end-points. Further studies are  
335 thus needed to assess the real impact of such variables on LR and OST.

336 To the authors' knowledge, this is the first report to evaluate the prognostic value of leukocyte  
337 counts and ratios in tumor-bearing cats. The prognostic impact of different leukocyte populations,  
338 however, has previously been assessed in both human and canine oncology. In human medicine,  
339 higher values of pretreatment NLR have been correlated with poorer prognosis for several solid

340 malignancies, including STS.<sup>22</sup> The prognostic/diagnostic value of different leukocyte populations,  
341 such as neutrophils, lymphocytes, eosinophils, and monocytes, and their ratios has been explored in  
342 canine solid and lymphoproliferative neoplasms.<sup>26-31,42</sup> In a recent paper, NLR was significantly  
343 higher in dogs with STS than in those with benign soft tissue lesions, although the parameter was  
344 not predictive of tumor grade.<sup>30</sup> In two further studies focusing on canine mast cell tumor, higher  
345 NLR was predictive of higher tumor grade and was correlated with poorer outcome in univariate  
346 analysis, although it was not confirmed as an independent prognostic factor for survival in  
347 multivariate analysis.<sup>29,31</sup> Neutrophilia has also been linked with tumor-associated systemic  
348 inflammatory response for different canine malignancies, such as oropharyngeal cancer and acute  
349 leukemia.<sup>24,42</sup> In a paper evaluating the prevalence of leukocyte populations in healthy, older, and  
350 tumor-bearing dogs, the authors reported that tumor-bearing dogs had a higher number of WBC and  
351 a higher percentage of neutrophils.<sup>43</sup> Such findings are consistent with the results in the present  
352 study.

353 The mechanism responsible for the relationship between leukocyte counts and ratio alterations and  
354 prognosis in human and veterinary oncology remains unclear. Indeed, tumor microenvironment and  
355 type of host immune response against cancer play a role in tumor development and progression.  
356 Neutrophils have both pro- and antitumor activities, but in cancer patients, neutrophilia has been  
357 linked with angiogenesis and tumor progression. Moreover, granulocytes and granulocyte-  
358 macrophage colony-stimulating factors are produced by some solid tumors and are known to  
359 modulate their progression in people<sup>44-45</sup>. On the other hand, T-lymphocyte subsets are crucial in  
360 specific antitumor immunity, and lymphopenia has been correlated with a worse prognosis in  
361 human patients with solid tumors.<sup>46</sup> As a consequence, a high NLR may reflect a less effective  
362 immune response against cancer, with a predominant neutrophilic response and relative  
363 lymphopenia, which promotes tumor growth and dissemination.<sup>23,43,47</sup>

364 In the light of such considerations, the absence of a correlation between LC and both LR and OST  
365 in the sampled population is surprising; however, it may be hypothesized that the efficacy of the  
366 host immune response against cancer is more influenced by the subpopulations of lymphocytes than  
367 by the absolute lymphocyte count, as suggested by results of previous studies on dogs.<sup>23,25,43</sup>

368 This report has several limitations, mainly related to its retrospective nature. The relatively low  
369 number of included cats resulted in a low number of events (24/82), which compromised the  
370 robustness of multivariate analysis. This consideration holds particularly true for multivariate  
371 analysis on LR, where the number of variables to be included in the model was decided following a  
372 less restrictive rule than the traditional EPV rule. However, a more robust bivariate model was  
373 performed and confirmed the results of multivariate analysis. Furthermore, when the relationship

374 between NLR, WBCC, NC, and LC and factors that may have altered leukocyte populations was  
375 explored, age, presence of concomitant diseases, and hyperglycemia were not associated with any  
376 of the above-mentioned hematology values, suggesting that such variables are unlikely to have an  
377 impact on them.

378 The decision to include cats that received adjuvant chemotherapy was mainly dictated by the fact  
379 that, to date, there is no strong evidence that such treatment is effective against LR, and it would  
380 thus have been unlikely to influence this endpoint.<sup>48-51</sup> In the sampled population, (4/6) 30% of cats  
381 treated with chemotherapy developed LR, while 18/76 (24%) of the cats that received only surgery  
382 reached this endpoint, suggesting a lack of impact of this treatment against LR. It might be argued  
383 that adjuvant chemotherapy may prevent distant metastasis, thus influencing OST, which was the  
384 secondary endpoint of the study; however, of the 24 cats that died due to tumor-related causes, only  
385 two had distant relapse, while the remaining 22 all experienced LR, suggesting that the impact of  
386 distant metastases on OST is negligible. Finally, in univariate analysis adjuvant chemotherapy was  
387 not significant for neither of the endpoints, suggesting the low impact of such treatment on  
388 outcome.

389 Strengths of this report are the homogeneity of patient management and long-term follow-up.  
390 Indeed, all cats were routinely staged, with most patients receiving a preoperative total body CT,  
391 definitive treatment consisted of curative-intent surgery for all patients, while cats that underwent  
392 neoadjuvant treatments were excluded; furthermore, we excluded patients that received  
393 radiotherapy as such treatment is reportedly effective against tumor recurrence.<sup>12,50,52</sup> Finally, the  
394 median follow-up of 1790 days allowed for a reliable observation of LR, including long-term  
395 recurrences.

396 In conclusion, pretreatment NLR, WBCC, and NC may be of value in identifying cats at higher risk  
397 of LR after curative-intent surgery for FISS. NLR, WBCC, and NC are readily available, cost-  
398 effective, and objective prognostic tools that can be easily retrieved from routine preoperative  
399 hematological work-up without the need for invasive examinations or adjunctive cost for the  
400 owners. However, the exploratory nature of this study impeded the identification of reliable  
401 thresholds, and further prospective studies are warranted to confirm the prognostic impact of these  
402 parameters on surgically excised FISS and to determine more accurate cut-offs.

403  
404  
405  
406  
407

408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438

## References

1. Ho NT, Smith KC, Dobromylskyj MJ. Retrospective study of more than 9000 feline cutaneous tumours in the UK: 2006-2013. *J Feline Med Surg* 2018;20(2):128-134.
2. Hartmann K, Day MJ, Thiry E, et al. Feline injection-site sarcoma: ABCD guidelines on prevention and management. *J Feline Med Surg* 2015; 17(7):606–613.
3. Morrison WB, Starr RM. Vaccine-Associated Feline Sarcoma Task Force. Vaccine-associated feline sarcomas. *J Am Vet Med Assoc* 2000;218(5):697-702.
4. Buracco P, Martano M, Morello E, Ratto A. Vaccine-associated-like fibrosarcoma at the site of a deep nonabsorbable suture in a cat. *Vet J* 2002;163(1):105-107.
5. Martano M, Morello E, Iussich S, Buracco P. A case of feline injection-site sarcoma at the site of cisplatin injections. *J Feline Med Surg* 2012;14(10):751-754.
6. Kass PH, Spangler WL, Hendrick MJ, et al. Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats. *J Am Vet Med Assoc* 2003;223(9):1283-1292.
7. Daly MK, Saba CF, Crochik SS, et al. Fibrosarcoma adjacent to the site of microchip implantation in a cat. *J Feline Med Surg* 2008;10(2):202-205.
8. Hershey AE, Sorenmo KU, Hendrick MJ, Shofer FS, Vail DM. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). *J Am Vet Med Assoc* 2000;216(1):58-61.

- 439 9. Bregazzi VS, LaRue SM, McNiel E, et al. Treatment with a combination of doxorubicin,  
440 surgery, and radiation versus surgery and radiation alone for cats with vaccine-associated  
441 sarcomas: 25 cases (1995-2000). *J Am Vet Med Assoc* 2001;218(4):547-550.
- 442 10. Poirier VJ, Thamm DH, Kurzman ID, et al. Liposome-encapsulated doxorubicin (Doxil)  
443 and doxorubicin in the treatment of vaccine-associated sarcoma in cats. *J Vet Intern Med*  
444 2002;16(6):726-731.
- 445 11. Romanelli G, Marconato L, Olivero D, Massari F, Zini E. Analysis of prognostic factors  
446 associated with injection-site sarcomas in cats: 57 cases (2001-2007). *J Am Vet Med*  
447 *Assoc* 2008;232(8):1193-1199.
- 448 12. Kobayashi T, Hauck ML, Dodge R, et al. Preoperative radiotherapy for vaccine  
449 associated sarcoma in 92 cats. *Vet Radiol Ultrasound* 2002;43(5):473-479.
- 450 13. Giudice C, Stefanello D, Sala M, et al. Feline injection-site sarcoma: recurrence, tumour  
451 grading and surgical margin status evaluated using the three-dimensional histological  
452 technique. *Vet J* 2010;186(1):84-88.
- 453 14. Phelps HA, Kuntz CA, Milner RJ, Powers BE, Bacon NJ. Radical excision with five-  
454 centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998-2002). *J*  
455 *Am Vet Med Assoc* 2011;239(1):97-106..
- 456 15. Müller N, Kessler M. Curative-intent radical en bloc resection using a minimum of a 3 cm  
457 margin in feline injection-site sarcomas: a retrospective analysis of 131 cases.  
458 *J Feline Med Surg* 2018;20(6):509-519.
- 459 16. Martano M, Morello E, Buracco P. Feline injection-site sarcoma: past, present and future  
460 perspectives. *Vet J* 2011;188(2):136-141.
- 461 17. Kuntz CA, Dernell WS, Powers BE, Devitt C, Straw RC, Withrow SJ. Prognostic factors  
462 for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). *J Am Vet*  
463 *Med Assoc* 1997;211(9):1147-1151.
- 464 18. Couto SS, Griffey SM, Duarte PC, Madewell BR. Feline vaccine-associated  
465 fibrosarcoma: morphologic distinctions. *Vet Pathol* 2002;39(1):33-41.
- 466 19. Bray J, Polton G. Neoadjuvant and adjuvant chemotherapy combined with anatomical  
467 resection of feline injection-site sarcoma: results in 21 cats. *Vet Comp Oncol*  
468 2016;14(2):147-160.

- 469 20. Hershey AE, Dubielzig RR, Padilla ML, Helfand SC. Aberrant p53 expression  
470 in feline vaccine-associated sarcomas and correlation with prognosis. *Vet Pathol*  
471 2005;42(6):805-811.
- 472 21. Porcellato I, Menchetti L, Brachelente C, et al. Feline injection-site sarcoma. *Vet Pathol*  
473 2017;54(2):204-211.
- 474 22. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-  
475 lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer*  
476 *Inst* 2014;106(6):1-11.
- 477 23. Karayannopoulou M, Anagnostou T, Margariti A, et al. Evaluation of blood T-  
478 lymphocyte subpopulations involved in host cellular immunity in dogs with mammary  
479 cancer. *Vet Immunol Immunopathol* 2017;186:45-50.
- 480 24. Rejec A, Butinar J, Gawor J, Petelin M. Evaluation of complete blood count indices  
481 (NLR, PLR, MPV/PLT, and PLCRi) in healthy dogs, dogs with periodontitis, and dogs  
482 with oropharyngeal tumors as potential biomarkers of systemic inflammatory response. *J*  
483 *Vet Dent* 2017;34(4):231-240
- 484 25. Watabe A, Fukumoto S, Komatsu T, Endo Y, Kadosawa T. Alterations of lymphocyte  
485 subpopulations in healthy dogs with aging and in dogs with cancer. *Vet Immunol*  
486 *Immunopathol* 2011;142(3-4):189-200.
- 487 26. Perry JA, Thamm DH, Eickhoff J, Avery AC, Dow SW. Increased monocyte chemotactic  
488 protein-1 concentration and monocyte count independently associate with a poor  
489 prognosis in dogs with lymphoma. *Vet Comp Oncol* 2011;9(1):55-64.
- 490 27. Marconato L, Martini V, Stefanello D, et al. Peripheral blood lymphocyte/monocyte ratio  
491 as a useful prognostic factor in dogs with diffuse large B-cell lymphoma receiving  
492 chemoimmunotherapy. *Vet J* 2015;206(2):226-230.
- 493 28. Sottnik JL, Rao S, Lafferty MH, et al. Association of blood monocyte and lymphocyte  
494 count and disease-free interval in dogs with osteosarcoma. *J Vet Intern Med*  
495 2010;24(6):1439-1444.
- 496 29. Macfarlane MJ, Macfarlane LL, Scase T, Parkin T, Morris JS. Use of neutrophil to  
497 lymphocyte ratio for predicting histopathological grade of canine mast cell tumours. *Vet*  
498 *Rec* 2016;179(19):491-503.



- 499 30. Macfarlane L, Morris J, Pratschke K, et al. Diagnostic value of neutrophil-lymphocyte  
500 and albumin-globulin ratios in canine soft tissue sarcoma. *J Small Anim Pract*  
501 2016;57(3):135-141.
- 502 31. Skor O, Fuchs-Baumgartinger A, Tichy A, Kleiter M, Schwendenwein I. Pretreatment  
503 leukocyte ratios and concentrations as predictors of outcome in dogs with cutaneous mast  
504 cell tumours. *Vet Comp Oncol* 2017;15(4):1333-1345.
- 505 32. Avallone G, Boracchi P, Stefanello D, Ferrari R, Rebughini A, Roccabianca P. Canine  
506 perivascular wall tumors: high prognostic impact of site, depth, and completeness of  
507 margins. *Vet Pathol* 2014;51(4):713-721.
- 508 33. Stromberg PC, Meuten DJ. Trimming Tumors for Diagnosis and Prognosis. In: Donald J.  
509 Meuten ed., *Tumors in Domestic Animals*. 5<sup>th</sup> ed., Ames, Iowa: Wiley Blackwell; 2017:  
510 35-51.
- 511 34. Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in  
512 medical research. *Malawi Med J* 2012;24(3):69-71.
- 513 35. Peterson AV. Bounds for a joint distribution function with fixed sub-distribution  
514 functions: Application to competing risk. *Proc Natl Acad Sci U S A*. 1976;73(1):11-13.
- 515 36. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent  
516 variable in proportional hazards regression analysis. II. Accuracy and precision of  
517 regression estimates. *J Clin Epidemiol* 1995;48(12):1503-1510.
- 518 37. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and  
519 COX regression. *Am J Epidemiol*. 2007;165(6):710-718.
- 520
- 521 38. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival  
522 data and a diagnostic marker. *Biometrics* 2000;56(2):337-344.
- 523 39. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time.  
524 *Control Clin Trials* 1996;17(4):343-346.
- 525 40. Nivy R, Itkin Y, Bdolah-Abram T, Segev G, Aroch I. Neutrophil counts and morphology  
526 in cats: a retrospective case-control study of 517 cases. *Isr J Vet Med* 2013;6(3):149-157.

- 528 41. Stefanello D, Buracco P, Sabattini S, Finotello R, Giudice C, Grieco V, et al. Comparison  
529 of 2- and 3-category histologic grading systems for predicting the presence of metastasis  
530 at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-  
531 2014). *J Am Vet Med Assoc*. 2015;246(7):765-769.
- 532 42. Novacco M, Comazzi S, Marconato L, et al. Prognostic factors in canine acute  
533 leukaemias: a retrospective study. *Vet Comp Oncol* 2016;14(4):409-416.
- 534 43. Itoh H, Horiuchi Y, Nagasaki T, et al. Evaluation of immunological status in tumor  
535 bearing dogs. *Vet Immunol Immunopathol* 2009;132(2-4):85-90.
- 536 44. Liu Q, Qiao L, Hu P, et al. The effect of granulocyte and granulocyte-macrophage colony  
537 stimulating factors on tumor promotion. *J Buon* 2017;22(1):21-28.
- 538 45. Hong IS. Stimulatory versus suppressive effects of GM-CSF on tumor progression in  
539 multiple cancer types. *Exp Mol Med* 2016;48(7):e242
- 540 46. Szkandera J, Gerger A, Liegl-Atzwanger B, et al. The derived neutrophil/lymphocyte ratio  
541 predicts poor clinical outcome in soft tissue sarcoma patients. *Am J Surg*  
542 2015;210(1):111-116.
- 543 47. Estrela-Lima A, Araújo MS, da Costa-Neto JM, et al. Understanding of the  
544 immunological heterogeneity of canine mammary carcinomas to provide  
545 immunophenotypic features of circulating leukocytes as clinically relevant prognostic  
546 biomarkers. *Breast Cancer Res Treat* 2012;131(3):751-763.
- 547 48. Barber LG, Sorenmo KU, Cronin KL, Shofer FS. Combined doxorubicin and  
548 cyclophosphamide chemotherapy for non-resectable feline fibrosarcoma. *J Am Anim Hosp*  
549 *Assoc* 2000;36:416-421.
- 550 49. Poirier VJ, Thamm DH, Kurzman ID, et al. Liposome-encapsulated doxorubicin (Doxil)  
551 and doxorubicin in the treatment of vaccine-associated sarcoma in cats. *J Vet Intern Med*  
552 2002;16:726-731.
- 553 50. Eckstein C, Guscetti F, Roos M, Martin de las Mulas J, Kaser-Hotz B, Rohrer BC. A  
554 retrospective analysis of radiation therapy for the treatment of feline vaccine-associated  
555 sarcoma. *Vet Comp Oncol* 2009;7:54-68.
- 556 51. Martano M, Morello E, Ughetto M, et al. Surgery alone versus surgery and doxorubicin  
557 for the treatment of feline injection-site sarcomas: a report on 69 cases. *Vet J*  
558 2005;170(1):84-90.

559 52. Rossi F, Marconato L, Sabattini S, et al. Comparison of definitive-intent finely  
 560 fractionated and palliative-intent coarsely fractionated radiotherapy as adjuvant treatment  
 561 of feline microscopic injection-site sarcoma. *J Feline Med Surg* 2019;21(2):65-72.

562

563

564 **Tables**

565

566 **Table 1.** References intervals for WBC, NC, LC in the cat.

Hematological parameter	Reference Interval
White Blood Cells (X 10 <sup>3</sup> /μL)	6.0 - 17
Neutrophil Count (X 10 <sup>3</sup> /μL)	3 – 13.4
Lymphocyte Count (X 10 <sup>3</sup> /μL)	2 – 7.2

567

568 **Table 2.** Comparison of Neutrophil/Lymphocyte ratio (NLR), Absolute Neutrophil Count (NC),  
 569 White Blood Cell Count (WBCC), †Lymphocyte Count (LC) distribution in the categories of  
 570 ulceration, necrosis, histology, concomitant disease and margins.

571

Variable	median,(Q1,Q3)	Mean(s.d.)	P
<b>NLR vs Ulceration</b> <sup>§</sup>			0.226
Absent	3.069(1.756, 4.730)	4.952(6.547)	
Present	3.199(2.555, 9.736)	7.476(8.009)	
<b>NC vs Ulceration</b> <sup>§</sup>			0.011*
Absent	3.482 (4.765, 6.970)	6.095(4.191)	
present	6.052 (7.250, 10.820)	12.730(14.007)	
<b>WBC vs Ulceration</b> <sup>§</sup>			0.007*
Absent	7.260(5.467, 10.400)	8.680(4.822)	
Present	10.680(9.018, 14.900)	16.010(13.880)	
<b>LC vs Ulceration</b> <sup>§</sup>			0.407
Absent	1.565(1.002, 2.530)	1.877(1.140)	
Present	2.120(1.720, 2.425)	2.056(0.713)	
<b>NLR vs Expansile/Infiltrative</b> <sup>§</sup>			0.024*
Infiltrative	3.405(2.331, 6.359)	6.695(8.531)	
Expansile	2.444(1.594, 3.749)	3.536(3.742)	

<b>NC vs Expansile/Infiltrative</b> <sup>§</sup> Infiltrative Expansile	4.230(5.880, 8.410) 3.102(4.040, 5.628)	8.311(7.768) 5.092(2.957)	0.004*
<b>WBC vs Expansile/Infiltrative</b> <sup>§</sup> Infiltrative Expansile	8.620(6.66, 11.53) 7.025(5.245, 9.310)	10.98(8.171) 7.800(3.707)	0.028*
<b>LC vs Expansile/Infiltrative</b> <sup>§</sup> Infiltrative Expansile	1.690(1.080, 2.420) 1.775(1.182, 2.688)	1.875(1.194) 1.986(1.015)	0.472
<b>NLR vs Necrosis</b> <sup>¶</sup> 0 1 2 3	3.280(1.760, 4.770) 2.281(1.762, 3.488) 2.696(1.680, 4.374) 3.628(2.186, 7.356)	5.458(6.148) 2.671(1.232) 3.616(2.689) 7.243(9.827)	0.401
<b>NC vs Necrosis</b> <sup>¶</sup> 0 1 2 3	3.895(4.700, 7.450) 3.325 (4.165, 5.690) 3.810 (4.710, 6.200) 3.710 (5.550, 9.808)	6.579(4.170) 4.492(1.709) 5.654(3.316) 8.524(9.077)	0.498
<b>WBC vs Necrosis</b> <sup>¶</sup> 0 1 2 3	8.100(6.295, 10.200) 6.200(5.072, 7.650) 7.240(6.020, 9.900) 8.805(5.872, 13.260)	9.255(4.374) 6.726(2.278) 8.536(4.706) 11.130(9.301)	0.360
<b>LC vs Necrosis</b> <sup>¶</sup> 0 1 2 3	2.030(0.980, 2.840) 1.785(1.495, 2.320) 1.710(1.240, 2.540) 1.465(1.062, 2.455)	1.931(0.993) 1.895(0.827) 2.100(1.372) 1.719(0.9425)	0.799
<b>NLR vs Histotype</b> <sup>§</sup> Fibrosarcoma other	2.619(1.705, 4.110) 3.752(2.347, 7.674)	4.682(7.130) 6.092(5.860)	0.029*
<b>NC vs Histotype</b> <sup>§</sup> Fibrosarcoma other	3.385 (4.765, 6.920) 4.358 (5.535, 9.962)	5.674(3.376) 8.594(8.769)	0.104
<b>WBC vs Histotype</b> <sup>§</sup> Fibrosarcoma other	7.135(5.542, 10.170) 8.845(6.050, 11.730)	8.368(4.130) 11.170(9.123)	0.187
<b>LC vs Histotype</b> <sup>§</sup> Fibrosarcoma Other	0.980(1.855, 2.630) 1.105(1.515, 2.258)	1.985(1.193) 1.737(0.927)	0.528
<b>NLR vs Concomitant</b>			0.600

<b>disease<sup>§</sup></b> Absent Present	3.279(2.050, 4.991) 2.539(1.823, 3.698)	4.801(4.844) 6.103(9.753)	
<b>NC vs Concomitant disease<sup>§</sup></b> Absent Present	3.830(4.960, 6.940) 3.520 (5.540, 7.500)	6.861(6.791) 6.472(4.022)	0.698
<b>WBC vs Concomitant disease<sup>§</sup></b> Absent Present	7.240(5.630, 10.950) 8.140(6.020, 10.560)	9.422(7.095) 9.332(5.058)	0.187
<b>LC vs Concomitant disease<sup>§</sup></b> Absent Present	1.040(1.600, 2.470) 1.240(1.690, 2.620)	1.856(1.002) 1.982(1.327)	0.840
<b>NLR vs Margins<sup>§</sup></b> Clean Dirty	2.700(1.710, 4.702) 3.405(2.539, 6.839)	4.676(5.367) 7.194(10.300)	0.1171
<b>NC vs Margins<sup>§</sup></b> Clean Dirty	3.520 (4.960, 6.500) 4.230(6.900, 10.400)	6.435(6.360) 7.919(4.713)	0.108
<b>WBC vs Margins<sup>§</sup></b> Clean Dirty	5.580(7.400, 9.500) 6.020(10.560, 11.820)	9.104(6.684) 10.51(5.852)	0.2146
<b>LC vs Margins<sup>§</sup></b> Clean Dirty	1.080 (1.710, 2.540) 0.980 (1.240, 2.470)	1.898( 0.971) 1.881( 1.549)	0.3815

572 <sup>§</sup>Wilcoxon Rank sum test; <sup>¶</sup>Kruskall-Wallis rank sum test; \* statistically significant at 5% level.

573

574

575 **Table 3.** Association between Neutrophil-to-Lymphocyte Ratio (NLR), Neutrophil Count (NC),  
576 White Blood Cells (WBC), Lymphocyte Count (LC) and size, glycemia and age.

577

578

<b>Variable</b>	<b>†r</b>	<b>95% CI</b>	<b>‡t (d.f.)</b>	<b>P</b>
<b>NLR vs Size</b>	0.315	0.104 – 0.499	2.955(79)	0.004*
<b>NC vs Size</b>	0.090	0.131 - 0.302	0.805 (79)	0.423
<b>WBC vs Size</b>	0.054	-0.167 - 0.268	0.478 (79)	0.631
<b>LC vs Size</b>	- 0.176	-0.380 - 0.044	-1.592 (79)	0.115
<b>NLR vs Glycemia</b>	0.036	-0.818 - 0.256	0.315(76)	0.734
<b>NC vs Glycemia</b>	0.070	-0.154 - 0.288	0.619(76)	0.537
<b>WBC vs Glycemia</b>	0.074	-0.150 - 0.292	0.653(76)	0.515
<b>LC vs Glycemia</b>	0.042	-0.182 - 0.262	0.369 (76)	0.718
<b>NLR vs Age</b>	0.072	-0.1472 - 0.285	0.646 (80)	0.520
<b>NC vs Age</b>	0.047	0.1716 - 0.261	0.421 (80)	0.674
<b>WBC vs Age</b>	0.091	-0.128 - 0.301	0.818 (80)	0.418
<b>LC vs Age</b>	0.59	-0.159- 0.273	0.534 (80)	0.593

579

598

599 †Pearson's correlation coefficient; ‡t statistics (d.f.) degree of freedom; \* statistically significant at  
600 5% level

601

602 **Table 4.** Univariate analysis of Neutrophil-to-Lymphocyte Ratio (NLR), Neutrophil Count (NC),  
603 White Blood Cells (WBC), Lymphocyte Count (LC) on Local Recurrence and Overall Survival.  
604 Cox model results and area under ROC curve.

Variable	Local recurrence		Overall survival	
	HR (95% C.I.)	P	HR (95% C.I.)	P
Sex M vs F	1.037 (0.449-2.395)	0.93	0.936 (0.558 -.570)	0.802
Age For each 1 year increase	1.046 (0.888-1.232)	0.59	1.15(1.034 -1.278)	0.01*
NLR For each 0.5 increase	1.066 (1.012- 1.122)	0.015*	1.045 (1.005-1.086)	0.028*
LC For each 100 cells increase	1.165 (0.776- 1.75)	0.462	1.103 (0.84-1.448)	0.482
NC For each 1000 cells increase	1.077 (1.025-1.132)	0.003*	1.048 (1.01-1.088)	0.014*
WBCC For each 1000 cells increase	1.078 (1.027 -1.132)	0.002*	1.048 (1.011-1.087)	0.011*
Glycemia For each unitary increase	1.002 (0.994-1.01)	0.631	0.999 (0.993-1.004)	0.68
Concomitant diseases Yes vs no	2.459 (1.02-5.929)	0.045*	1.637 (0.904-2.967)	0.104
Ulceration Yes vs no	5.062 (1.384-18.51)	0.014*	5.29 (2.233-12.54)	< 0.001*
Tumour Size For each cm increase	1.073 (0.954-1.208)	0.241	1.095 (1.025-1.171)	0.007*
Expansive/infiltrative Expansive vs infiltrative	0.267 (0.096-0.746)	0.012*	0.605 (0.351-1.043)	0.071
Necrosis 1 vs 0 2 vs 0 3 vs 0	1.003 (0.167-6.012) 1.051 (0.263-4.209) 1.844 (0.497-6.841)	0.643 0.998 0.944 0.360	0.853 (0.290-2.508) 1.173 (0.514-2.678) 1.522 0.675 3.433	0.541 0.772 0.705 0.311
Margins Dirty vs clean	2.584 (1.00- 6.674)	0.050*	2.531 (1.387-4.617)	0.002*
Histotype Other vs Fibrosarcoma	0.893(0.364-2.191)	0.805	1.174 (0.688-2.004)	0.557
Adjuvant. Therapies Yes vs no	1.629 (0.55-4.827)	0.378	1.393 (0.679-2.856)	0.366

605 \*Statistically significant at 5% level.

606 **Table 5.** Multivariate analysis of Neutrophil-to-Lymphocyte Ratio (NLR), Neutrophil Count (NC),  
607 White Blood Cells (WBC), Lymphocyte Count (LC) on Local recurrence.  
608 Results of the Backward selection procedure applied to Cox model to adjust hematological  
609 parameters for the variables that were statistically significant in univariate analysis.

<b>Model for NLR*</b>		
<b>Variable</b>	<b>HR (95% C.I.)</b>	<b>P</b>
NLR For each 0.5 increase	1.064 (1.012 -1.118)	0.016*
Concomitant diseases Yes vs no	2.940 (1.168 -7.404)	0.022*
Ulceration Yes vs no	7.393 (1.835-29.786)	0.005*
Margins Dirty vs clean	2.659 (1.000 -7.072)	0.050*
<b>Model for WBCC**</b>		
<b>Variable</b>	<b>HR (95% C.I.)</b>	<b>P</b>
WBCC For each 1000 cells increase	1.085 (1.029 -1.144)	0.003*
Concomitant disease Yes vs no	3.647 (1.408 -9.444)	0.008*
Ulceration Yes vs no	5.046 (1.159-21.960)	0.031*
Margins Dirty vs clean	3.055 (1.152 -8.104)	0.025*
<b>Model for NC**</b>		
<b>Variable</b>	<b>HR (95% C.I.)</b>	<b>P</b>
Neu For each 1000 cells increase	1.084 (1.026 -1.144)	0.004*
Concomitant diseases Yes vs no	3.587 (1.387 -9.277)	0.008*
Ulceration Yes vs no	5.032 (1.143-22.145)	0.033*
Margins Dirty vs clean	3.019 (1.138 -8.007)	0.026*

610 \*Statistically significant at 5% level. \*\*Expansile/Infiltrative was removed by the Backward  
611 selection because not statistically significant.

612



613 **Table 6.** Multivariate analysis of Neutrophil-to-Lymphocyte Ratio (NLR), Neutrophil Count (NC),  
 614 White Blood Cells (WBC), Lymphocyte Count (LC) on Overall Survival.

<b>Model for NLR**</b>		
<b>Variable</b>	<b>HR (95% C.I.)</b>	<b>P</b>
NLR For each 0.5 increase	1.028 (0.985-1.073)	0.206
Age For each 1 year increase	1.170 (1.051-1.303)	0.004*
Ulceration Yes vs no	7.352 (2.950-18.325)	<0.0001*
Margins Dirty vs clean	2.337 (1.256 -4.351)	0.007*
Tumour size For each 1 cm increase	1.101 (1.022 -1.186)	0.012
<b>Model for WBCC**</b>		
<b>Variable</b>	<b>HR (95% C.I.)</b>	<b>P</b>
WBCC For each 1000 cells increase	1.033 (0.993-1.075)	0.111
Age For each 1 year increase	1.171 (1.052 -1.303)	0.004*
Ulceration Yes vs no	6.521 (2.559-16.621)	<0.0001*
Margins Dirty vs clean	2.434 (1.305 -4.541)	0.005*
Tumour size For each 1 cm increase	1.115 (1.037-1.198)	0.003*
<b>Model for NC**</b>		
<b>Variable</b>	<b>HR (95% C.I.)</b>	<b>P</b>
Neu For each 1000 cells increase	1.032 (0.990-1.076)	0.141
Age For each 1 year increase	1.173 (1.054 -1.306)	0.003*
Ulceration Yes vs no	6.650 (2.614-16.917)	<0.0001*
Margins Dirty vs clean	2.395 (1.286-4.459)	0.006*
Tumor size For each 1 cm increase	1.114 (1.036-1.197)	0.003*

615 \*Statistically significant at 5% level. \*\*NLR, WBCC, NC were removed by Backward selection  
 616 procedure because not statistically significant. The variable that made NLR, WBCC and NC not  
 617 significant was ulceration.

618 **Figure legends**

619

620 **Figure 1**

621 Kaplan-Meier estimated local recurrence-free survival probability (continuous line) and 95%  
622 confidence intervals (dotted lines).

623

624 **Figure 2**

625 Kaplan-Meier estimated survival probability (continuous line) and 95% confidence intervals (dotted  
626 lines).